World News | Bangladesh's First Native Covid Vaccine Bangavax Receives Nod for Human Trials
Get latest articles and stories on World at LatestLY. Bangladesh's first homegrown vaccine has received approval from the Bangladesh Medical Research Council (BMRC) for human trials.
Dhaka [Bangladesh], November 24 (ANI): Bangladesh's first homegrown vaccine has received approval from the Bangladesh Medical Research Council (BMRC) for human trials.
Senior manager for quality and regulation AT Directorate General of Drug Administration (DGDA) stated that the manufacturer of Bangavax, Globe Biotech is set to send DGDA human trial protocol, reported the Daily Star.
Also Read | South Korea Confirms First Foetus Death Due to COVID-19.
After the single-dose vaccine, Bangavax gets assent for clinical trials from DGDA, Globe Biotech will initiate human trials, said DGDA senior manager.
Globe Biotech on October 5 the previous year, revealed that its first vaccine candidate had shown promise in pre-clinical trials on mice, reported the Daily Star.
Bangavax was initially known as Bancovid. (ANI)
(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)